We are thrilled to announce that DeepSeq.AI has been accepted into two of the most prestigious accelerator programs in the biotech industry with pre-seed funding: the Merck Digital Sciences Studio and UC-Berkeley’s SkyDeck. These achievements mark a significant milestone in our mission to revolutionize large molecule drug discovery through our cutting-edge AI platform and screening technologies.
Merck Digital Sciences Studio (DSS), a leading collaborative initiative between Merck and the New Jersey Innovation Institute, with investments by Merck GHI, Northpond Ventures, and McKesson Ventures, and technology support by Microsoft, focuses on accelerating digital innovation in healthcare. Our inclusion in the Merck DSS program not only validates our technology but also provides us with unique opportunities to collaborate with industry leaders and leverage Merck's extensive expertise in pharmaceutical development.
Berkeley SkyDeck is a leading global accelerator renowned for its robust network and resources that empower startups to scale and succeed. With an acceptance rate of just 1.3%, being part of this program offers us unparalleled access to Berkeley's world-class research, mentorship, and investment opportunities, enabling us to further enhance our AI-driven solutions.
These accelerator programs significantly enhance our capabilities in providing pharmaceutical companies with highly novel, functional, and manufacturable large-molecule drugs. Our explainable Generative AI platform, combined with proprietary large-scale wet-lab screening methods, enables us to model protein "grammar" and optimize critical drug properties effectively.
Our participation in the Berkeley SkyDeck and Merck DSS programs underscores our commitment to advancing AI-driven drug discovery and showcases the industry's recognition of our innovative approach. We look forward to leveraging these opportunities to accelerate our growth and deliver transformative solutions to our partners and clients.
For potential investors and customers, these milestones highlight the growing recognition and support for DeepSeq.AI's vision and technology. We are excited to continue our journey, driving innovation and creating impactful solutions in the pharmaceutical industry.
Stay tuned for more updates as we embark on this exciting new chapter!
